{"name":"Nippon Kayaku Co., Ltd.","slug":"nippon-kayaku-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NK105","genericName":"NK105","slug":"nk105","indication":"Breast cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NKT-01","genericName":"NKT-01","slug":"nkt-01","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"NK105","genericName":"NK105","slug":"nk105","phase":"phase_3","mechanism":"NK105 is a nanosomal formulation of paclitaxel, a microtubule inhibitor.","indications":["Breast cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"NKT-01","genericName":"NKT-01","slug":"nkt-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNNmpLVGR0RXlFVXBkNW1ma0llVXNmenNjS2lvTnVuYUNGY1VJSkdvZU1TaDlTVXBjbjRsSUVOZjN4dVBuZ0JGMHpiWkh3enlpZVVURTJKbFFsUGVQamxPMjYtX1dsQ0VLOEFRSkNPRUdicWlyVmdWcVI5RDJUTXpsbm5rcTY1TG9paXJGQmczMFBpMGx5Mmwwa2pueWpaTk1yZGVTVnZvZUpjNUpvM3FlNVRaWjdXcW5XNUp3eFFBcnMwNEJvUFNVbXRfT1JmRTBGeExGR2hncDVKQQ?oc=5","date":"2026-04-07","type":"deal","source":"The Globe and Mail","summary":"Nippon Kayaku Completes ¥16.2 Billion Share Buyback Program - The Globe and Mail","headline":"Nippon Kayaku Completes ¥16.2 Billion Share Buyback Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWExPcFExd2htbktsbXdZVVB0ZG11bFUxSzFpNHJLeER3NXBaMF9UMUhqclZaWnFhd2U4Yk41YU1ySlMtUkg3SDJEbmoweGoxUkxWWWZ2S3NLV0xwaFhkUU45SHBpcGRITV9vZGZ6SEdkdGcyN2JTcllfSmd6X1VxQjlJVmRXNVRxLVJXV1VxeVB6N1BtNFlWLWgxQllXWW1wV1lKdXFseHRJR2dZc1dveFJwV2RraXJnV2Mwc3RaZ1pjZw?oc=5","date":"2026-04-03","type":"pipeline","source":"AD HOC NEWS","summary":"Nippon Kayaku Co Ltd stock: Why this Japanese chemicals player deserves your watchlist - AD HOC NEWS","headline":"Nippon Kayaku Co Ltd stock: Why this Japanese chemicals player deserves your watchlist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNMUxhZTVxVWQ3elNRVWh3eHJMeG9QWGJGcUZ4b3VVdnluWTJwN3FUYXpFQkl6V1pvdTdZUk1GZW42bk5qM1BNS0hwb0JHWUVfcVEtWThLUm5nbUtwQ0NaZHBYNG1oWTNFN3BHMlFZOFI2ZmxhVVVGYzlUY294cERoLTh6UXo5VTU1R3lESWhxem1CckZ0SFJEOHQyaFl3bkEwYzFnRFBkVTZOdTlTa3MxV2w4aW9qNWQyWGd6UG5saE9PRHpXRmc?oc=5","date":"2026-04-03","type":"pipeline","source":"AD HOC NEWS","summary":"Nippon Kayaku Co Ltd Stock: A Deep Dive into Japan's Diversified Chemicals Leader for North American - AD HOC NEWS","headline":"Nippon Kayaku Co Ltd Stock: A Deep Dive into Japan's Diversified Chemicals Leader for North American","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPdGhNNzQ0WGVianREMENSRWREbDlTX01OOUhUQko3cW5ERUxESHBPb3dtdXU4VjFsN29jT05qOERLb2NZZkIyaU5sU0pQdUROQklXNnR6M2lKdXpxMUpyN254QlV6UHlVWHVMc3ZqeDgzVUdLV3lvSG1xdGtQUGwxcXRfd0hzNFlNa19ZSFowRzNhalVFTUd3TjlzMEhBdml0OThoYzFlWjBWUEFQSGhKYjg0S29fY2x5RldrOWJHaGV5cXM?oc=5","date":"2026-03-30","type":"pipeline","source":"AD HOC NEWS","summary":"Nippon Kayaku Co Ltd Stock: A Deep Dive into Japan's Specialty Chemicals Leader for North American I - AD HOC NEWS","headline":"Nippon Kayaku Co Ltd Stock: A Deep Dive into Japan's Specialty Chemicals Leader for North American I","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNZlhhdGRYYWZ6YVBTUEtMYW9Hd3NuMms0UTFRSVQ2WjJva2syM2NfQ1UxcmhSUURVTWt6ekN4OE1OeURsWkdlN3N5RzhjTTZjM0NNMTZxMmNLM1hydDdETUlObVVJWXNQeUJzZzlhQjJjUHBVWFkzZVJ1T2lQeVJMSlc0Qlo2UUdJaW00dHNMZm5qYTNLM2MzMEJFZl9BZllGdjhUOExXZ0JoOTJLRWpJ?oc=5","date":"2026-03-23","type":"deal","source":"Contract Pharma","summary":"GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate - Contract Pharma","headline":"GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNjByejhEZHpjMDhtLWFvQWQtdXBtb0ZkbkFXbE5Ob3FwUFgxX3RQLURPRF91UlBJMEhiMnQ0N21RaV9Kc0dOVmd5eGphVDd6STNLMm5VSzNLajZnVllZNzhOSXFqYk9wTm91a1hRZXlQcGQ3U2VsWl8xX3d4QWNpWDY5amlCWmxjbDhqclZyY3NRanZPb3FwSzctNGlXRmZqdGRLRDA5Ylo3cTIwUXpIUkl1U0pHVzJSX21iVmpzTDZsWGFkVDNWV24xcjVhcWVNRkprZ3d6STNpbEkzZmhPNDNZckZnZ3FlYVkxbnBVdm9aNHV4TEVnaw?oc=5","date":"2026-03-23","type":"deal","source":"prnewswire.com","summary":"GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC - prnewswire.com","headline":"GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBLem5VTHRhZ0JWT2NsajlqRVhDMzFrcVdtTHdtWHYtSTFmcHAxeWdZUXhMdnZuSG5ZZndob1BOLUxjcmdPVUF5VzgtZ0R1NDl4UVFQMVkxVEdmdGtXSlhoS3pkQ3E5V2YxX1E?oc=5","date":"2025-12-02","type":"pipeline","source":"Wiley Online Library","summary":"Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis - Wiley Online Library","headline":"Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNR0kxV0VZNzlpZnVBSUpjRHdHQ0hsTkh5enVRcnNRWGJ3VGRDR29VSGtFWjN2NnpUQVVsYVB1cnM0MVFrOHV1YTBPQTFXLWJSQVFEcXpubjdkYVg0VWs3NXc5U2ZGZ3l4LVdOLTByU1liSkdiaS1VZm1LUkwxaE1Ra1hmak9CeE9ObWtjamxrWWxTajhDVENjVU5MZHM1aUFfN2Q4TEYyMEZwYzgxeWp4M0prX2p4azRoRFVUbTJB?oc=5","date":"2025-08-27","type":"deal","source":"BioSpectrum Asia","summary":"Japan's Nippon to establish Singapore-based JV to license drugs in Asia - BioSpectrum Asia","headline":"Japan's Nippon to establish Singapore-based JV to license drugs in Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNSkZMTjQzTXF6YXRXNTllQTJWTWZXWm5ZX0RLWGpaVkIwTFVSVjgwUVlhcTdfNGRwVEV6WFZya0MyOWk2c2FvS3hfUmRHSklMU2I5N2R5OTVyQk9HWkRZZjZJa3ctSExxaVAzYzBDeEhFZkljQnVGaTRBeGdMaEhsdG4zcldnVTlqUUVfa2pDd2ZSYk1FVHdxaGZPUDM4dEVIZG4wWmV3NWZoVEQ3X0daeVRYaHk3TEhKNmZadUJzM21FMWVwcXBNSmlYbkdPVUlQQ0E1SGh2TEZYZ21LSWZ0QVlxa0NGeDgtXy03VllRelBpVGN2T1pDZjFlQWoyZ2hQZUhlMXhRcDAzVDVSTU1hN3NKamtrWG9tMWhQLWZYVWxvbEVMVTRrNWQ5QzJaUU43VzFEMEEwcHU3VU0yZjRlNmFxemlNUnBWVk15Y0E5d1ltWWc?oc=5","date":"2025-05-15","type":"pipeline","source":"GlobeNewswire","summary":"Nivolumab Market Report 2025-2029 & 2034: Innovative - GlobeNewswire","headline":"Nivolumab Market Report 2025-2029 & 2034: Innovative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTWc4NS01V0JwaDlqV0ZIbFBNbEZneDI0b3E2YkpjckpVV3JuNUMtSjk3M3pNMHFwM05ERW9zMlBBTmtoeTNuZVI0dFdzb2JKY2J4ZzFOMXhYMzRVakZ2aWYtMVlpQnBUTTc0WlRKQ0wzVFVNV0ZEZHZiMFQ5RElPY2hBRVNCR1BWdm1oTEJwcXFsVklnTTZwUWFlc0x0aVlzemJUNUlQVXhLNEZCbXJuZmhfT253cTZr?oc=5","date":"2024-09-12","type":"pipeline","source":"Asia Research News |","summary":"BMI’s relation to cancer therapy mortality risks not so straightforward - Asia Research News |","headline":"BMI’s relation to cancer therapy mortality risks not so straightforward - Asia Research News |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPRENoNDZRNnQ5UExBa2ZwMEVUbG0yS3NXN0dMV09CNHR5RHgxSVhrUDhmUDVjZnJXTklNX3lLaUVaYXdKLXpoYlpuYTBWTVdxV2FvWWpVcjBCSG5nMnp0T3VkOFFQY2wwdTQ1OXpxVTZHbEY4SC04NXZaNS1WV2MyclNaSFV1dHhBdGl2SmhnLVN5QUozcjBnS04wVUZ2WVpQWWV3V05XSzJZS0stTFhyNU5VeEFFcU1LeWhwUVRwRE1oSDRQa1JiUmRHb0pDYzdiZVFXQzQzOXJYRXRHNlVvYnpzdUxPZFlZTEotU2V4MjhlQQ?oc=5","date":"2021-10-26","type":"deal","source":"businesswire.com","summary":"Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02) - businesswire.com","headline":"Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}